Medidata Solutions announced that its electronic data capture (EDC) and clinical data management (CDM) solution Medidata Rave has been selected by OptiNose US, Inc.to capture clinical trial data across all studies.
“The company’s selection of Rave speaks volumes about the comfort and trust in our technologies at all levels–from sponsors of all sizes to investigators across the globe.”
Founded in 2000, OptiNose is focused on the development of breakthrough bi-directional nasal drug delivery technology which significantly improves drug transport to targeted sites deep into the nasal cavity. The company is currently planning clinical research programs for the treatment of migraine headaches, nasal polyposis and chronic sinusitis. In assessing potential systems, OptiNose looked for a user-friendly, affordable EDC system that could potentially reduce time to database lock across global trials.
“The product’s ease-of-use and the company’s global presence provide benefits for our clinical development team, as well as our investigators, many of whom are familiar with the Medidata system,” commented Jennifer Carothers, senior director of clinical development, OptiNose.
Leveraging Medidata Rave’s global library to create standard electronic case report forms (eCRFs) will help OptiNose accelerate EDC set-up across their trials. Research teams, including site investigators, will also benefit from Rave’s broad data reporting capabilities, including out of the box J-Review reports for simplified ad-hoc clinical data analysis.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.